LB-BrainScan

TRIPLE-MRD-SCAN references

MM-LIBISCAN references

2024

168. Pyrimidine-Dependent UV-Mediated Cross-Linking Magnifies Minor Genetic or Epigenetic Changes in Clinical Samples, Fangyan Yu*, Farzana Ahmed*, Stavroula Smilkou*, Sayeda Yasmin-Karim, Farzaneh Darbeheshti, Athina Markou, Martyn Bullock, Ioannis Boukovinas, Viktor A Adalsteinsson, Evi Lianidou, G Mike Makrigiorgos, Clin Chem, 2024 Jul 23:hvae086.

167. Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients, Argyro Roumeliotou, Areti Strati, Foteini Chamchougia, Anastasia Xagara, Victoria Tserpeli, Stavroula Smilkou, Elina Lagopodi, Athina Christopoulou, Emmanouil Kontopodis, Ioannis Drositis, Nikolaos Androulakis, Vassilis Georgoulias, Filippos Koinis, Athanasios Kotsakis, Evi Lianidou, Galatea Kallergi, Cells, 2024 May 3;13(9):782.

166. Multiplex detection of ten ESR1 mutations and AKT1 E17K in breast cancer using digital PCR, Stavroula Smilkou, Aliki Ntzifa, Dimitra Stergiopoulou, Vasilis Georgoulias, Evi Lianidou, The Journal of Liquid Biopsy Volume 5, September 2024, 100154

165. Liquid biopsy for the management of NSCLC patients under osimertinib treatment, Aliki Ntzifa, Theodoros Marras, Vasilis Georgoulias, Evi Lianidou, Review, Crit Rev Clin Lab Sci. 2024 Feb 2:1-23.

2023

164. Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis, Aliki Ntzifa, Evi Lianidou. Crit. Rev. Clin. Lab. Sci. 2023 Dec;60(8):573-594

163. Highly Sensitive Detection Method of CXCR4 Tumor Hotspot Mutations by Drop-Off Droplet Digital PCR in Patients with IgM Monoclonal Gammopathies, Athina N. Markou, Tina Bagratuni, Christina Tsakiri, Victoria Tserpeli, Stamatia Skourti, Nefeli Mavrianou Koutsoukou, Alexandra Papadimou, Evangelos Terpos, Efstathios Kastritis, Evi Lianidou, and Meletios-Athanasios Dimopoulos, J Mol Diagn. 2023 Jul;25(7):502-512

162. Development and Validation of a Novel Dual-Drop-off ddPCR Assay for the Simultaneous Detection of Ten Hotspots PIK3CA Mutations, Dimitra Stergiopoulou, Stavroula Smilkou, Vasilis Georgoulias, Loukas Kaklamanis, Evi Lianidou, Athina Markou. Anal. Chem. 2023, 95, 37, 14068–14076

161. Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy, Areti Strati, Panagiota Economopoulou, Evi Lianidou, Amanda Psyrri. Biomedicines 2023, 11(6), 1768; https://doi.org/10.3390/biomedicines11061768

160. Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting, Areti Strati, Athina Markou, Evgenia Kyriakopoulou, Evi Lianidou. Cancers 2023, 15(7), 2185; https://doi.org/10.3390/cancers15072185

159. Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer, A. N. Markou, D. Londra, D. Stergiopoulou, I. Vamvakaris, K. Potaris, I. S. Pateras, A. Kotsakis, V. Georgoulias, E. Lianidou. Cancers 2023, 15(6), 1877; https://doi.org/10.3390/cancers15061877

158. Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer, Dimitra Stergiopoulou, Athina Markou, Areti Strati, Martha Zavridou, Eleni Tzanikou, Sophia Mastoraki, Galatea Kallergi, Vassilis Georgoulias, Evi Lianidou. Sci Rep. 2023 Jan 23;13(1):1258. doi: 10.1038/s41598-022-25400-1.

2022

157. Development and Analytical Validation of a 6-Plex Reverse Transcription Droplet Digital PCR Assay for the Absolute Quantification of Prostate Cancer Biomarkers in Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer, Martha Zavridou, Stavroula Smilkou, Victoria Tserpeli, Aggeliki Sfika, Evangelos Bournakis, Areti Strati, Evi Lianidou. Clin Chem. 2022 Oct 6;68(10):1323-1335. doi: 10.1093/clinchem/hvac125.

156. Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer, Karolina Buszka, Aliki Ntzifa, Barbara Owecka, Paula Kamińska, Agata Kolecka-Bednarczyk, Maciej Zabel, Michał Nowicki, Evi Lianidou, Joanna Budna-Tukan. Review, Cells. 2022 Sep 14;11(18):2871. doi: 10.3390/cells11182871.

155. The potential of liquid biopsy in the management of cancer patients, A Markou, E Tzanikou, E Lianidou. Review, Semin Cancer Biol. 2022 Sep;84:69-79. doi: 10.1016/j.semcancer.2022.03.013.

154. Development and Analytical Validation of a One-Step Five-Plex RT-ddPCR Assay for the Quantification of SARS-CoV-2 Transcripts in Clinical Samples, Areti Strati, Martha Zavridou, Dimitrios Paraskevis, Gkikas Magiorkinis, Spyros Sapounas, Pagona Lagiou, Nikolaos S Thomaidis, Evi S Lianidou, Anal Chem. 2022 Sep 13;94(36):12314-12322. doi: 10.1021/acs.analchem.2c00868. Epub 2022 Aug 12.

153. Detection of ESR1 Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients, Dimitra Stergiopoulou, Athina Markou, Lydia Giannopoulou, Paul Buderath, Ioanna Balgkouranidou, Nikolaos Xenidis, Stylianos Kakolyris, Sabine Kasimir-Bauer, and Evi Lianidou, Cancers (Basel).2022 Aug; 14(15): 3790. Published online 2022 Aug 4. doi: 10.3390/cancers14153790

152. PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC), Evangelia Pantazaka, Aliki Ntzifa, Argyro Roumeliotou, Evi Lianidou, Vassilis Georgoulias, Athanasios Kotsakis and Galatea Kallergi, Biomedicines. 2022 Aug; 10(8): 1893. Published online 2022 Aug 5. doi: 10.3390/biomedicines10081893 

151. Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy, Galatea Kallergi, Emmanouil Kontopodis, Aliki Ntzifa, Núria Jordana-Ariza, Niki Karachaliou, Evangelia Pantazaka, Haris A Charalambous, Amanda Psyrri, Emily Tsaroucha, Ioannis Boukovinas, Anna Koumarianou, Dora Hatzidaki, Evi Lianidou, Vassilis Georgoulias, Rafael Rosell, Athanasios Kotsakis, Cancers (Basel). 2022 Mar 19;14(6):1574. doi: 10.3390/cancers14061574.

 150. The value proposition of integrative diagnostics for (early) detection of cancer. On behalf of the EFLM interdisciplinary Task and Finish Group "CNAPS/CTC for early detection of cancer", Matthias F Froelich, Ettore Capoluongo, Zsolt Kovacs, Simon J Patton, Evi S Lianidou, Verena Haselmann, Clin Chem Lab Med. 2022 Feb 24;60(6):821-829 doi: 10.1515/cclm-2022-0129.

149. Metabolism-Related Gene Expression in Circulating Tumor Cells from Patients with Early Stage Non-Small Cell Lung Cancer, Zafeiriadou A, Kollias I, Londra T, Tsaroucha E, Georgoulias V, Kotsakis A, Lianidou E, Markou A, Cancers 2022, 14(13), 3237; https://doi.org/10.3390/cancers14133237

148.  DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection, Α. Markou, D. Londra, V. Tserpeli, Ι. Kollias, E. Tsaroucha, I. Vamvakaris, K. Potaris, I. Pateras, Α. Kotsakis, V. Georgoulias & Ε. Lianidou, Clinical Epigenetics volume 14, Article number: 61 (2022), Published: 10 May 2022, PMID: 35538556, PMCID: PMC9092693, DOI: 10.1186/s13148-022-01283-x

2021

147. Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer, Victoria Tserpeli, Dimitra Stergiopoulou, Dora Londra, Lydia Giannopoulou, Paul Buderath, Ioanna Balgkouranidou, Nikolaos Xenidis, Christina Grech, Eva Obermayr, Robert Zeillinger, Kitty Pavlakis, Theodoros Rampias, Stylianos Kakolyris, Sabine Kasimir-Bauer, Evi S. Lianidou, Cancers 2021 Dec 21;14(1):4. doi: 10.3390/cancers14010004

146. DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment, Aliki Ntzifa, Dora Londra, Theodoros Rampias, Athanasios Kotsakis, Vassilis Georgoulias, Evi Lianidou, Cancers 2021, 13(23), 5974; https://doi.org/10.3390/cancers13235974

145. USP44 Promoter Methylation in Plasma Cell-Free DNA in Prostate Cancer, Dora Londra, Sophia Mastoraki, Evangelos Bournakis, Martha Zavridou, Anastasios Thanos, Theodoros Rampias, Evi S Lianidou, Cancers (Basel). 2021 Sep 14;13(18):4607.

144. A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer, Areti Strati, Martha Zavridou, Galatea Kallergi, Eleni Politaki, Andra Kuske, Tobias M Gorges, Sabine Riethdorf, Simon A Joosse, Claudia Koch, Anna-Lena Bohnen, Volkmar Mueller, George Koutsodontis, Emmanouil Kontopodis, Nikiforita Poulakaki, Amanda Psyrri, Dimitris Mavroudis, Vasilis Georgoulias, Klaus Pantel, Evi S Lianidou, Clin Chem. 2021 Oct 1;67(10):1395-1405.

143. The Effect of Genomic DNA Contamination on the Detection of Circulating Long Non-Coding RNAs: The Paradigm of MALAT1, Athina N Markou, Stavroula Smilkou, Emilia Tsaroucha, Evi Lianidou, Diagnostics (Basel). 2021 Jun 25;11(7):1160.

142. Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR, Aliki Ntzifa, Athanasios Kotsakis, Vassilis Georgoulias, Evi Lianidou, Cancers (Basel). 2021 May 31;13(11):2736.

141. Generation of Non-Small Cell Lung Cancer Patient-Derived Xenografts to Study Intratumor Heterogeneity, Zoi Kanaki, Alexandra Voutsina, Athina Markou, Ioannis S Pateras, Konstantinos Potaris, Margaritis Avgeris, Periklis Makrythanasis, Emmanouil I Athanasiadis, Ioannis Vamvakaris, Eleni Patsea, Konstantinos Vachlas, Evi Lianidou, Vassilis Georgoulias, Athanasios Kotsakis, Apostolos Klinakis, Cancers (Basel). 2021 May 18;13(10):2446.

140. Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook, Evi Lianidou, Review, Mol Oncol. 2021 Jun; 15(6): 1683–1700.

139. Prognostic Role of RASSF1A, SOX17 and Wif-1 Promoter Methylation Status in Cell-Free DNA of Advanced Gastric Cancer Patients, Evangelos I Karamitrousis, Ioanna Balgkouranidou, Nikolaos Xenidis, Kyriakos Amarantidis, Eirini Biziota, Triantafyllia Koukaki, Grigorios Trypsianis, Anastasios Karayiannakis, Helen Bolanaki, George Kolios, Evi Lianidou, Stylianos Kakolyris, Technol Cancer Res Treat. 2021; 20: 1533033820973279.

138. RNA-Based CTC Analysis Provides Prognostic Information in Metastatic Breast Cancer, Areti Strati, Michail Nikolaou, Vassilis Georgoulias, Evi S Lianidou, Diagnostics (Basel). 2021 Mar 14;11(3):513.

137. Prognostic Significance of Gene Expression and DNA Methylation Markers in Circulating Tumor Cells and Paired Plasma Derived Exosomes in Metastatic Castration Resistant Prostate Cancer, Martha Zavridou, Areti Strati, Evangelos Bournakis, Stavroula Smilkou, Victoria Tserpeli, Evi Lianidou, Cancers (Basel). 2021 Feb 13;13(4):780.

136. Androgen Receptor and PIM1 Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer, Aliki Ntzifa, Areti Strati, Georgia-Angeliki Koliou, Flora Zagouri, Dimitrios Pectasides, George Pentheroudakis, Christos Christodoulou, Helen Gogas, Christina Magkou, Constantina Petraki, Paris Kosmidis, Gerasimos Aravantinos, Vassiliki Kotoula , George Fountzilas, Evi Lianidou, Cancer Genomics Proteomics. 2021 Mar-Apr; 18(2): 147–156.

135. ESR1 NAPA Assay: Development and Analytical Validation of a Highly Sensitive and Specific Blood-Based Assay for the Detection of ESR1 Mutations in Liquid Biopsies, Dimitra Stergiopoulou, Athina Markou, Eleni Tzanikou, Ioannis Ladas, G Mike Makrigiorgos, Vassilis Georgoulias, Evi Lianidou, Cancers (Basel). 2021 Feb 1;13(3):556.

134. Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients, Aliki Ntzifa, Areti Strati, Galatea Kallergi, Athanasios Kotsakis, Vassilis Georgoulias, and Evi Lianidou, Sci Rep. 2021; 11: 2313.

132. KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer, Sofia Mastoraki, Ioanna Balgkouranidou, Emily Tsaroucha, Apostolos Klinakis, Vassilis Georgoulias, Evi Lianidou, Mol Oncol. 2021 Sep; 15(9): 2412–2422.

 

2020

131. Association between SOX17, Wif-1 and RASSF1A promoter methylation status and response to chemotherapy in patients with metastatic gastric cancer, Evangelos Karamitrousis, Ioanna Balgkouranidou, Nikolaos Xenidis, Kyriakos Amarantidis, Eirini Biziota, Triantafyllia Koukaki, Gregorios Trypsianis, Anastasios Karayiannakis, Heleni Bolanaki, Ekaterini Chatzaki, Georgios Kolios, Evi Lianidou, Maria Lambropoulou and Stylianos Kakolyris, 
Clinical Chemistry and Laboratory Medicine (CCLM)

130. Liquid Biopsy in Ovarian Cancer.
Giannopoulou L, Lianidou E
Adv Clin Chem 2020;97:13-71
Abstract link: https://pubmed.ncbi.nlm.nih.gov/32448432

129. PIM-1 Is Overexpressed at a High Frequency in Circulating Tumor Cells From Metastatic Castration-Resistant Prostate Cancer Patients.
Markou A, Tzanikou E, Strati A, Zavridou M, Mastoraki S, Bournakis E, Lianidou E
Cancers (Basel) 2020 May 8;12:E1188
Abstract link: https://pubmed.ncbi.nlm.nih.gov/32397108/

128. Direct comparison of size-dependent versus EpCAM-dependent CTC enrichment at the gene expression and DNA methylation level in head and neck squamous cell carcinoma. 
Zavridou M, Mastoraki S, Strati A, Koutsodontis G, Klinakis A, Psyrri A, Lianidou E
Sci Rep 2020 Apr;10:6551
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/32300118

127. Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients.
Tzanikou E, Haselmann V, Markou A, Duda A, Utikal J, Neumaier M, Lianidou ES
Clin Chem Lab Med 2020 Jan 18 [Epub ahead of print]
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/31953992

126. The potential of ctDNA analysis in breast cancer. 
Tzanikou E, Lianidou E
Crit Rev Clin Lab Sci 2020 Jan;57:54-72
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/31674269

2019

125. Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows.
Lampignano R, Neumann MHD, Weber S, Kloten V, Herdean A, Voss T, Groelz D, Babayan A, Tibbesma M, Schlumpberger M, Chemi F, Rothwell DG, Wikman H, Galizzi JP, Bergheim IR, Russnes H, Mussolin B, Bonin S, Voigt C, Musa H, Pinzani P, Lianidou E, Brady G, Speicher MR, Pantel K, Betsou F, Schuuring E, Kubista M, Ammerlaan W, Sprenger-Haussels M, Schlange T, Heitzer E; Innovative Medicines Initiative CANCER-ID Consortium
Clin Chem 2019 Oct 18 [Epub ahead of print]
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/31628139

124. Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer.
Strati A, Zavridou M, Bournakis E, Mastoraki S, Lianidou E
Analyst 2019 Nov;144:6671-6680
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/31596277 

123. NaME-PrO-assisted ARMS (NAPA): a novel approach for the improvement of ARMS-PCR specificity in liquid biopsies.
Markou A, Tzanikou E, Ladas I, Makrigiorgos M, Lianidou ES
Anal Chem 2019 Oct 15;91:13105-13111
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/31538770

122. Prognostic Significance of TWIST1, CD24, CD44, and ALDH1 Transcript Quantification in EpCAM-Positive Circulating Tumor Cells from Early Stage Breast Cancer Patients.
Strati A, Nikolaou M, Georgoulias V, Lianidou ES
Cells 2019 Jun 29;8 [Epub ahead of print]
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/31261917

121. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
Tzanikou E, Markou A, Politaki E, Koutsopoulos A, Psyrri A, Mavroudis D, Georgoulias V, Lianidou E
Mol Oncol 2019 Jun 29 [Epub ahead of print]
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/31254443

120. Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC).
Economopoulou P, Koutsodontis G, Strati A, Kirodimos E, Giotakis E, Maragoudakis P, Prikas C, Papadimitriou N, Perisanidis C, Gagari E, Kotsantis I, Vagia E, Anastasiou M, Gkotzamanidou M, Kavourakis G, Lianidou E, Psyrri A
Oral Oncol 2019 Jul;94:93-100
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/31178219

119. A pilot plasma-ctDNA ring trial for the Cobas® EGFR Mutation Test in clinical diagnostic laboratories.
Ntzifa A, Kroupis C, Haliassos A, Lianidou E
Clin Chem Lab Med 2019 Apr;57:e97-e101
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/30267626

118. Liquid Biopsies.
Lianidou E, Pantel K
Genes Chromosomes Cancer 2019 Apr;58:219-232
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/30382599

117. Development and validation of Multiplex Liquid Bead Array (MLBA) assay for the simultaneous expression of fourteen genes in Circulating Tumor Cells (CTCs)
Parisi CA, Markou A, Strati A, Kasimir-Bauer S, Lianidou ES
Anal Chem 2019 Mar;91:3443-3451
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/30663875

116. Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes.
Giannopoulou L, Zavridou M, Kasimir-Bauer S, Lianidou ES
Transl Res 2019 Mar;205:77-91
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/30391474

2018

115. Evaluation of Preanalytical Conditions and Implementation of Quality Control Steps for Reliable Gene Expression and DNA Methylation Analyses in Liquid Biopsies.
Zavridou M, Mastoraki S, Strati A, Tzanikou E, Chimonidou M, Lianidou E
Clin Chem 2018 Oct;64:1522-1533
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/30018056

114. ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer.
Giannopoulou L, Mastoraki S, Buderath P, Strati A, Pavlakis K, Kasimir-Bauer S, Lianidou ES
Gynecol Oncol 2018 Aug;150:355-360
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/29807696

113. ESR1 methylation: a liquid biopsy-based epigenetic assay for the follow up of patients with metastatic breast cancer receiving endocrine treatment.
Mastoraki S, Strati A, Tzanikou E, Chimonidou M, Politaki H, Voutsina A, Psyrri A, Georgoulias V, Lianidou ES
Clin Cancer Res 2018 Mar;24:1500-1510
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/29284708

112. Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients.
Markou A, Lazaridou M, Paraskevopoulos P, Chen S, Świerczewska M, Budna J, Kuske A, Gorges TM, Joosse SA, Kroneis T, Zabel M, Sedlmayr P, Alix-Panabières C, Pantel K, Lianidou ES
Clin Chem 2018 Feb;64:297-306
Abstract link:https://www.ncbi.nlm.nih.gov/pubmed/29122836

111. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA.
Giannopoulou L, Kasimir-Bauer S, Lianidou ES
Clin Chem Lab Med 2018 Jan 26;56:186-197
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/28753534

2017

110. DNA and Histone Methylation in Lung Cancer.
Mastoraki S, Lianidou E.
DNA and Histone Methylation as Cancer Targets 2017 pp 403-436
Abstract link: https://link.springer.com/chapter/10.1007%2F978-3-319-59786-7_15

109. A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer.
Politaki E, Agelaki S, Apostolaki S, Hatzidaki D, Strati A, Koinis F, Perraki M, Saloustrou G, Stoupis G, Kallergi G, Spiliotaki M, Skaltsi T, Lianidou E, Georgoulias V, Mavroudis D
Cell Physiol Biochem 2017;44:594-606
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/29161698

108. Editorial on “Gene expression signatures in circulating tumor cells correlate with response to therapy in metastatic breast cancer”
Strati A, Georgoulias V
J Lab Precis Med 2017 Dec 15. doi: 10.21037/jlpm.2017.12.05

107. Liquid biopsy: An emerging prognostic and predictive tool in Head and Neck Squamous Cell Carcinoma (HNSCC). Focus on Circulating Tumor Cells (CTCs).
Economopoulou P, Kotsantis I, Kyrodimos E, Lianidou ES, Psyrri A
Oral Oncol 2017 Nov;74:83-89
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/29103757

106. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.
Strati A, Koutsodontis G, Papaxoinis G, Angelidis I, Zavridou M, Economopoulou P, Kotsantis I, Avgeris M, Mazel M, Perisanidis C, Sasaki C, Alix-Panabières C, Lianidou E, Psyrri A
Ann Oncol 2017 Aug;28:1923-1933
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/28838214

105. Exosomes: A Cancer Theranostics Road Map.
Panagiotara A, Markou A, Lianidou ES, Patrinos GP, Katsila T
Public Health Genomics 2017;20:116-125
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/28723694

104. Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer.
Chimonidou M, Strati A, Malamos N, Kouneli S, Georgoulias V, Lianidou E
Oncotarget 2017 Jun;8:72054-72068
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/28674207

103. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
Giannopoulou L, Chebouti I, Pavlakis K, Kasimir-Bauer S, Lianidou ES
Oncotarget 2017 Mar;8:21429-21443
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/28206954

2016

102. Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients.
Kuske A, Gorges TM, Tennstedt P, Tiebel AK, Pompe R, Preißer F, Prues S, Mazel M, Markou A, Lianidou E, Peine S, Alix-Panabières C, Riethdorf S, Beyer B, Schlomm T, Pantel K
Sci Rep 2016 Dec;6:39736
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/28000772

101. Development and validation of a multiplex methylation specific PCR-coupled liquid bead array for liquid biopsy analysis.
Parisi C, Mastoraki S, Markou A, Strati A, Chimonidou M, Georgoulias V, Lianidou ES
Clin Chim Acta 2016 Oct;461:156-64
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/27510924

100. SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer.
Balgkouranidou I, Chimonidou M, Milaki G, Tsaroucha E, Kakolyris S, Georgoulias V, Lianidou E
Clin Chem Lab Med 2016 Aug;54:1385-93
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/26741346

99. Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients.
Markou A, Zavridou M, Sourvinou I, Yousef G, Kounelis S, Malamos N, Georgoulias V, Lianidou E
Clin Chem 2016 Jul;62:1002-11
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/27197674

98. Gene expression profiling and DNA methylation analyses of CTCs.
Lianidou ES
Mol Oncol 2016 Mar;10:431-42
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/26880168

97. miRNA-21 as a novel therapeutic target in lung cancer.
Markou A, Zavridou M, Lianidou ES.
Lung Cancer 2016 Mar 2;7:19-27
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/28210157

2015

96. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients.
Balgkouranidou I, Matthaios D, Karayiannakis A, Bolanaki H, Michailidis P, Xenidis N, Amarantidis K, Chelis L, Trypsianis G, Chatzaki E, Lianidou ES, Kakolyris S.
Mutat Res 2015 Aug;778:46-51
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/26073472

95. MicroRNA signatures as clinical biomarkers in lung cancer.
Markou A, Zavridou M, Lianidou ES.
Curr Biomark Find 2015;5:35-45 

94. A rapid and accurate closed-tube Methylation-Sensitive High Resolution Melting Analysis assay for the semi-quantitative determination of SOX17 promoter methylation in clinical samples.
Mastoraki S, Chimonidou M, Dimitrakopoulos L, Kounelis S, Malamos N, Georgoulias V, Lianidou E.
Clin Chim Acta 2015 Apr;444:303-9
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/25727515

93. The Role of CTCs as Tumor Biomarkers.
Lianidou ES, Markou A, Strati A.
Adv Exp Med Biol 2015;867:341-67
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/26530376

92. Metastasis-related miRNAs: a new way to differentiate patients with higher risk?
Markou A, Lianidou E, Georgoulias V.
Future Oncol 2015;11:365-7
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/25675118

2014

91. Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey.
Liu W, Vivian CJ, Brinker AE, Hampton KR, Lianidou E, Welch DR
Cancer Microenviron 2014 Dec;7:117-31
Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/24938990

90. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.
Markou A, Farkona S, Schiza C, Efstathiou T, Kounelis S, Malamos N, Georgoulias V, Lianidou E.
Clin Cancer Res 2014 Nov;20:5823-34
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/25398847

89. Molecular characterization of circulating tumor cells: Holy Grail for personalized cancer treatment?
Lianidou ES
Clin Chem 2014 Oct;60:1249-51
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/25142245

88. Advancing the education in molecular diagnostics: the IFCC-Initiative "Clinical Molecular Biology Curriculum" (C-CMBC); a ten-year experience.
Lianidou E, Ahmad-Nejad P, Ferreira-Gonzalez A, Izuhara K, Cremonesi L, Schroeder ME, Richter K, Ferrari M, Neumaier M.
Clin Chim Acta 2014 Sep;436:5-8
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/24815033

87. Circulating tumor cells as promising novel biomarkers in solid cancers.
Lianidou ES, Strati A, Markou A.
Crit Rev Clin Lab Sci 2014 Jun;51:160-71
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/24641350

86. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer.
Balgkouranidou I, Chimonidou M, Milaki G, Tsarouxa EG, Kakolyris S, Welch DR, Georgoulias V, Lianidou ES.
Br J Cancer 2014 Apr;110:2054-62
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/24642624

85. Circulating tumor cell isolation: a marathon race worth running.
Lianidou ES.
Clin Chem 2014 Feb;60:287-9

84. Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up.
Markou A, Yousef GM, Stathopoulos E, Georgoulias V, Lianidou E.
Clin Chem 2014 Jan;60:197-205
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/24132943

2013

83. Advances in circulating tumor cells (ACTC): from basic research to clinical practice.
Lianidou ES, Mavroudis D, Pantel K.
Breast Cancer Res 2013 Dec;15:319
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/24314311

82. Quantification of Circulating miRNAs in Plasma: Effect of Preanalytical and Analytical Parameters on Their Isolation and Stability.
Sourvinou IS, Markou A, Lianidou ES.
J Mol Diagn 2013 Nov;15:827-34
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/23988620

81. Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer.
Lianidou ES, Mavroudis D, Georgoulias V.
Br J Cancer 2013 Jun;108:2426-32
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/23756869

80. Clinical evaluation of microRNA expression profiling in non small cell lung cancer.
Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E.
Lung Cancer 2013 Sep;81:388-96
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/23756108 

79. Breast Cancer Metastasis Suppressor-1 promoter methylation in primary breast tumors and corresponding Circulating Tumor Cells.
Chimonidou M, Kallergi G, Georgoulias V, Welch DR, Lianidou ES.
Mol Cancer Res 2013 Oct;11:1248-57
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/23744981

78. Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer.
Strati A, Kasimir-Bauer S, Markou A, Parisi C, Lianidou ES.
Breast Cancer Res 2013 Mar 7;15:R20
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/23497487

77. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival.
Balgkouranidou I, Karayiannakis A, Matthaios D, Bolanaki H, Tripsianis G, Tentes AA, Lianidou E, Chatzaki E, Fiska A, Lambropoulou M, Kolios G, Kakolyris S.
Clin Chem Lab Med 2013 Jul;51:1505-10
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/23403728

76. Lung cancer epigenetics: emerging biomarkers.
Balgkouranidou I, Liloglou T, Lianidou ES.
Biomark Med 2013 Feb;7:49-58
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/23387484

75. CST6 promoter methylation in circulating cell-free DNA of breast cancer patients.
Chimonidou M, Tzitzira A, Strati A, Sotiropoulou G, Sfikas C, Malamos N, Georgoulias V, Lianidou E
Clin Biochem 2013 Feb;46:235-40
Abstract link: www.ncbi.nlm.nih.gov/pubmed/23006792

74. SOX17 Promoter Methylation in Circulating Tumor Cells and Matched Cell-Free DNA 
Isolated from Plasma of Patients with Breast Cancer.
Chimonidou M, Strati A, Malamos N, Georgoulias V, Lianidou ES.
Clin Chem 2013 Jan;59:270-9
Abstract link: www.ncbi.nlm.nih.gov/pubmed/23136251

2012

73. A closed-tube methylation-sensitive high resolution melting assay (MS-HRMA) for the semi-quantitative determination of CST6 promoter methylation in clinical samples.
Dimitrakopoulos L, Vorkas PA, Georgoulias V, Lianidou ES.
BMC Cancer 2012 Oct 22;12:486
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/23088560

72. Molecular characterization of circulating tumor cells in breast cancer challenges and promises for individualized cancer treatment.
Lianidou ES, Markou A, Strati A.
Cancer Metastasis Rev 2012 Dec;31:663-71
Abstract link: www.ncbi.nlm.nih.gov/pubmed/22692478.1

71. Molecular Assays for the Detection and Characterization of CTCs.
Lianidou ES, Markou A.
Recent Results Cancer Res 2012;195:111-23
Abstract link: www.ncbi.nlm.nih.gov/pubmed/22527499.1 

70. Circulating tumor cells--new challenges ahead.
Lianidou ES
Clin Chem 2012 May;58:805-7

69. Development of a multiplexed PCR-coupled liquid bead array assay for vascular endothelial growth factor (VEGF) splice variants.
Parisi C, Markou A, Lianidou ES.
Clin Biochem 2012 Apr;45:475-82
Abstract link: www.ncbi.nlm.nih.gov/pubmed/22330939

2011

68. Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR.
Strati A, Markou A, Parisi C, Politaki E, Mavroudis D, Georgoulias V, Lianidou E.
BMC Cancer 2011 Oct;11:422
Abstract link: www.ncbi.nlm.nih.gov/pubmed/21967632

67. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay.
Markou A, Strati A, Malamos N, Georgoulias V, Lianidou ES.
Clin Chem 2011 Mar;57:421-30
Abstract link: www.ncbi.nlm.nih.gov/pubmed/21245367

66. Circulating Cancer Cells and Their Clinical Applications.
Diamandis EP, Pantel K, Scher HI, Terstappen L, Lianidou E.
Clin Chem 2011 Nov;57:1478-84

65. Circulating tumor cells as emerging tumor biomarkers in breast cancer.
Lianidou E, Markou A.
Clin Chem Lab Med 2011 Oct;49:1579-90
Abstract link: www.ncbi.nlm.nih.gov/pubmed/21801030

64. Circulating tumor cells (CTC) in breast cancer: detection systems, molecular characterization and future challenges.
Lianidou E, Markou A.
Clin Chem 2011 Sep;57:1242-55
Abstract link: www.ncbi.nlm.nih.gov/pubmed/217847663.

63. DNA methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells.
Chimonidou M, Strati A, Tzitzira A, Sotiropoulou G, Malamos N, Georgoulias V, Lianidou ES.
Clin Chem 2011 Aug;57:1169-77
Abstract link: www.ncbi.nlm.nih.gov/pubmed/21700955

62. Prognostic and diagnostic potential of microRNAs in non-small cell lung cancer.
Markou A, Liang Y, Lianidou E.
Clin Chem Lab Med 2011 Oct;49:1591-603
Abstract link: www.ncbi.nlm.nih.gov/pubmed/21767219

2010

61. What's new on circulating tumor cells? A meeting report.
Lianidou ES, Mavroudis D, Sotiropoulou G, Agelaki S, Pantel K.
Breast Cancer Res 2010 Jul;12:307
Abstract link: www.ncbi.nlm.nih.gov/pubmed/20727231

60. PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method.
Vorkas PA, Poumpouridou N, Agelaki S, Kroupis C, Georgoulias V, Lianidou ES.
J Mol Diagn 2010 Sep;12:697-704
Abstract link: www.ncbi.nlm.nih.gov/pubmed/20616362

59. Mutation scanning of exon 20 of the BRCA1 gene by high-resolution melting curve analysis.
Vorkas PA, Christopoulos K, Kroupis C, Lianidou ES.
Clin Biochem 2010 Jan;43:178-85
Abstract link: www.ncbi.nlm.nih.gov/pubmed/19747471

2009

58. Quantitative analysis of heparanase gene expression in normal cervical, cervical intraepithelial neoplastic, and cervical carcinoma tissues.
Varchalama E, Rodolakis A, Strati A, Papageorgiou T, Valavanis C, Vorgias G, Lianidou E, Antsaklis A.
Int J Gynecol Cancer 2009 Dec;19:1614-9
Abstract link: www.ncbi.nlm.nih.gov/pubmed/19955948

57. Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients.
Kallergi G, Markomanolaki H, Giannoukaraki V, Papadaki MA, Strati A, Lianidou ES, Georgoulias V, Mavroudis D, Agelaki S.
Breast Cancer Res 2009;11:R84
Abstract link: www.ncbi.nlm.nih.gov/pubmed/19919679

56. MicroRNAs in clinical oncology: at the crossroads between promises and problems.
Metias SM, Lianidou E, Yousef GM.
J Clin Pathol 2009 Sep;62:771-6
Abstract link: www.ncbi.nlm.nih.gov/pubmed/19734473

55. Systemic hypertension augments, whereas insulin-dependent diabetes down-regulates, endothelin A receptor expression in the mammary artery in coronary artery disease patients.
Zygalaki E, Kaklamanis L, Lolaka M, Nikolaou N, Koutouzis M, Lianidou ES, Kyriakides ZS.
Cardiol J 2009;16:348-54
Abstract link: www.ncbi.nlm.nih.gov/pubmed/19653178

54. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis.
Chow TF, Youssef YM, Lianidou E, Romaschin AD, Honey RJ, Stewart R, Pace KT, Yousef GM.
Clin Biochem 2010 Jan;43:150-8
Abstract link: www.ncbi.nlm.nih.gov/pubmed/19646430

53. Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell.
Sotiropoulou G, Pampalakis G, Lianidou E, Mourelatos Z.
RNA 2009 Aug;15:1443-61
Abstract link: www.ncbi.nlm.nih.gov/pubmed/19561119

52. Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer.
Kioulafa M, Balkouranidou I, Sotiropoulou G, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES.
Int J Cancer 2009 Dec 15;125:2887-92.
Abstract link: www.ncbi.nlm.nih.gov/pubmed/19551853

51. Effect of ellagic acid on the expression of human telomerase reverse transcriptase (hTERT) alpha+beta+ transcript in estrogen receptor-positive MCF-7 breast cancer cells.
Strati A, Papoutsi Z, Lianidou E, Moutsatsou P.
Clin Biochem 2009 Sep;42:1358-62
Abstract link: www.ncbi.nlm.nih.gov/pubmed/19501078

50. Prognostic significance of RASSF1A promoter methylation in operable breast cancer.
Kioulafa M, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES.
Clin Biochem 2009 Jul;42:970-5
Abstract link: www.ncbi.nlm.nih.gov/pubmed/19374895

49. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.
Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, Georgoulias V, Mavroudis D.
J Clin Oncol 2009 May;27:2177-84
Abstract link: www.ncbi.nlm.nih.gov/pubmed/19332733

48. Distinct neutrophil subpopulations phenotype by flow cytometry in myelodysplastic syndromes.
Vikentiou M, Psarra K, Kapsimali V, Liapis K, Michael M, Tsionos K, Lianidou E, Papasteriades C.
Leuk Lymphoma 2009 Mar;50:401-9
Abstract link: www.ncbi.nlm.nih.gov/pubmed/19294559

47. Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer.
Kioulafa M, Kaklamanis L, Stathopoulos E, Mavroudis D, Georgoulias V, Lianidou ES.
Ann Oncol 2009 Jun;20:1020-5
Abstract link: www.ncbi.nlm.nih.gov/pubmed/19150938

2008

46. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR.
Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES.
Clin Chem 2008 Oct;54:1696-704
Abstract link: www.ncbi.nlm.nih.gov/pubmed/18719201

45. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.
Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulias V, Mavroudis D.
Clin Cancer Res 2008 May;14:2593-600
Abstract link: www.ncbi.nlm.nih.gov/pubmed/18451221

44. Endothelin system and atrial fibrillation post-cardiac surgery.
Kolettis TM, Kyriakides ZS, Zygalaki E, Kyrzopoulos S, Kaklamanis L, Nikolaou N, Lianidou ES, Kremastinos DT.
J Interv Card Electrophysiol 2008 Apr;21:203-8
Abstract link: www.ncbi.nlm.nih.gov/pubmed/18264746

43. Asymmetric real-time PCR detection of BRCA1 5382insC mutation by melting curve analysis in the LightCycler.
Kroupis C, Christopoulos K, Devetzoglou M, Tsiagas I, Lianidou ES.
Clin Chim Acta 2008 Apr;390:141-4
Abstract link: www.ncbi.nlm.nih.gov/pubmed/18242166

42. Expression profile of total VEGF, VEGF splice variants and VEGF receptors in the myocardium and arterial vasculature of diabetic and non-diabetic patients with coronary artery disease.
Zygalaki E, Kaklamanis L, Nikolaou NI, Kyrzopoulos S, Houri M, Kyriakides Z, Lianidou ES, Kremastinos DT.
Clin Biochem 2008 Jan;41:82-7
Abstract link: www.ncbi.nlm.nih.gov/pubmed/17961532

2007

41. Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer.
Ignatiadis M, Perraki M, Apostolaki S, Politaki E, Xenidis N, Kafousi M, Stathopoulos E, Lianidou E, Sotiriou C, Georgoulias V, Mavroudis D.
Clin Breast Cancer 2007 Dec;7:883-9
Abstract link: www.ncbi.nlm.nih.gov/pubmed/18269779

40. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D.
J Clin Oncol 2007 Nov;25:5194-202
Abstract link: www.ncbi.nlm.nih.gov/pubmed/17954712

39. Quantitative real-time reverse transcription PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non small cell lung cancer.
Zygalaki E, Tsaroucha EG, Kaklamanis L, Lianidou ES.
Clin Chem 2007 Aug;53:1433-9
Abstract link: www.ncbi.nlm.nih.gov/pubmed/17599955

38. Real-time RT-PCR quantification of human telomerase reverse transcriptase splice variants in tumor cell lines and non-small cell lung cancer.
Mavrogiannou E, Strati A, Stathopoulou A, Tsaroucha EG, Kaklamanis L, Lianidou ES.
Clin Chem 2007 Jan;53:53-61
Abstract link: www.ncbi.nlm.nih.gov/pubmed/17130181

2006

37. Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR.
Ntoulia M, Stathopoulou A, Ignatiadis M, Malamos N, Mavroudis D, Georgoulias V, Lianidou ES.
Clin Biochem 2006 Sep;39:879-87
Abstract link: www.ncbi.nlm.nih.gov/pubmed/16925986

36. HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization.
Ntoulia M, Kaklamanis L, Valavanis C, Kafousi M, Stathopoulos E, Arapantoni P, Mavroudis D, Georgoulias V, Lianidou ES.
Clin Biochem 2006 Sep;39:942-6
Abstract link: www.ncbi.nlm.nih.gov/pubmed/16916505

35. Presence of high-risk human papillomavirus sequences in breast cancer tissues and association with histopathological characteristics.
Kroupis C, Markou A, Vourlidis N, Dionyssiou-Asteriou A, Lianidou ES.
Clin Biochem 2006 Jul;39:727-31
Abstract link: www.ncbi.nlm.nih.gov/pubmed/16780823

34. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients.
Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C, Argyraki K, Lianidou ES, Stathopoulos S, Georgoulias V, Mavroudis D.
J Clin Oncol 2006 Aug;24:3756-62
Abstract link: www.ncbi.nlm.nih.gov/pubmed/16769987

33. A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer.
Stathopoulou A, Ntoulia M, Perraki M, Apostolaki S, Mavroudis D, Malamos N, Georgoulias V, Lianidou ES.
Int J Cancer 2006 Oct;119:1654-9
Abstract link: www.ncbi.nlm.nih.gov/pubmed/16708381

2005

32. Real-time reverse transcription-PCR quantification of vascular endothelial growth factor splice variants.
Zygalaki E, Stathopoulou A, Kroupis C, Kaklamanis L, Kyriakides Z, Kremastinos D, Lianidou ES.
Clin Chem 2005 Aug;51:1518-20
Abstract link: www.ncbi.nlm.nih.gov/pubmed/16040847

31. Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA.
Kroupis C, Stathopoulou A, Zygalaki E, Ferekidou L, Talieri M, Lianidou ES.
Clin Biochem 2005 Jan;38:50-7
Abstract link: www.ncbi.nlm.nih.gov/pubmed/15607317

2004

30. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.
Bozionellou V, Mavroudis D, Perraki M, Papadopoulos S, Apostolaki S, Stathopoulos E, Stathopoulou A, Lianidou E, Georgoulias V.
Clin Cancer Res 2004 Dec;10:8185-94
Abstract link: www.ncbi.nlm.nih.gov/pubmed/15623593

29. Genetic counseling of medullary breast cancer patients.
Kroupis C, Lianidou E, Goutas N, Vasilaros S, Yannoukakos D, Petersen MB.
Clin Genet 2004 Apr;65:343-4
Abstract link: www.ncbi.nlm.nih.gov/pubmed/15025730

28. Effect of antineoplastic agents on the expression of human telomerase reverse transcriptase beta plus transcript in MCF-7 cells.
Spiropoulou T, Ferekidou L, Angelopoulou K, Stathopoulou A, Talieri M, Lianidou ES.
Clin Biochem 2004 Apr;37:299-304
Abstract link: www.ncbi.nlm.nih.gov/pubmed/15003732

2003

27. Development of a highly sensitive RT-PCR luminometric hybridization assay for human telomerase reverse-transcriptase beta-plus transcript.
Angelopoulou K, Spiropoulou T, Stathopoulou A, Dimitroulopoulos D, Malamos N, Georgoulias V, Paraskevas E, Lianidou ES.
Anticancer Res 2003 Nov-Dec;23:4821-9
Abstract link: www.ncbi.nlm.nih.gov/pubmed/14981931

26. Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system.
Stathopoulou A, Gizi A, Perraki M, Apostolaki S, Malamos N, Mavroudis D, Georgoulias V, Lianidou ES.
Clin Cancer Res 2003 Nov;9:5145-51.
Abstract link: www.ncbi.nlm.nih.gov/pubmed/14613993

25. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers.
Stathopoulou A, Mavroudis D, Perraki M, Apostolaki S, Vlachonikolis I, Lianidou E, Georgoulias V.
Anticancer Res 2003 Mar-Apr;23:1883-90
Abstract link: www.ncbi.nlm.nih.gov/pubmed/12820473

24. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer.
Xenidis N, Vlachonikolis I, Mavroudis D, Perraki M, Stathopoulou A, Malamos N, Kouroussis C, Kakolyris S, Apostolaki S, Vardakis N, Lianidou E, Georgoulias V.
Ann Oncol 2003 Jun;14:849-55
Abstract link: www.ncbi.nlm.nih.gov/pubmed/12796021

23. Atypical medullary breast carcinoma in a family carrying the 5382insC BRCA-1 mutation.
Kroupis C, Lianidou E, Goutas N, Ladopoulou A, Konstantopoulou I, Pantazidis A, Yannoukakos D, Efstathiou E, Vourlidis N, Tsionou C.
Breast J 2003; May-Jun;9:260-2
Abstract link: www.ncbi.nlm.nih.gov/pubmed/12752644  

2000 - 2002

22. Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed.
Ladopoulou A, Kroupis C, Konstantopoulou I, Ioannidou-Mouzaka L, Schofield AC, Pantazidis A, Armaou S, Tsiagas I, Lianidou E, Efstathiou E, Tsionou C, Panopoulos C, Mihalatos M, Nasioulas G, Skarlos D, Haites NE, Fountzilas G, Pandis N, Yannoukakos D.
Cancer Lett 2002 Nov 8;185:61-70
Abstract link: www.ncbi.nlm.nih.gov/pubmed/12142080

21. Quantitative RT-PCR luminometric hybridization assay with an RNA internal standard for cytokeratin-19 mRNA in peripheral blood of patients with breast cancer.
Stathopoulou A, Angelopoulou K, Perraki M, Georgoulias V, Malamos N, Lianidou ES.
Clin Biochem 2001 Nov;34:651-9
Abstract link: www.ncbi.nlm.nih.gov/pubmed/11849626

20. Development of a quantitative luminometric hybridization assay for the determination of telomerase activity.
Kolioliou M, Talieri M, Lianidou ES.
Clin Biochem 2001 Jun;34:277-84
Abstract link: www.ncbi.nlm.nih.gov/pubmed/11440727

19. BRCA1 mutation analysis in breast/ovarian cancer families from Greece.
Konstantopoulou I, Kroupis C, Ladopoulou A, Pantazidis A, Boumba D, Lianidou ES, Petersen MB, Florentin L, Chiotellis E, Nounesis G, Efstathiou E, Skarlos D, Tsionou C, Fountzilas G, Yannoukakos D Hum Mutat 2000 Sep;16:272-3
Abstract link: www.ncbi.nlm.nih.gov/pubmed/10980541

1987 - 1999

18. Characterization of the BRCA1-like immunoreactivity of human seminal plasma.
Angelopoulou K, Borchert G, Melegos DN, Lianidou E, Lilja H, Diamandis EP.
Urology 1999 Oct;54:753-62
Abstract link: www.ncbi.nlm.nih.gov/pubmed/10510943

17. Determination of tumor necrosis factor-alpha (TNF-alpha) in serum by a highly sensitive enzyme amplified lanthanide luminescence immunoassay.
Petrovas C, Daskas SM, Lianidou ES.
Clin Biochem 1999 Jun;32:241-7
Abstract link: www.ncbi.nlm.nih.gov/pubmed/10463815

16. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma.
Lianidou ES, Levesque MA, Katsaros D, Angelopoulou K, Yu H, Genta F, Arisio R, Massobrio M, Bharaj B, Diamandis EP.
Anticancer Res 1999 Jan-Feb;19:749-56
Abstract link: www.ncbi.nlm.nih.gov/pubmed/10216487

15. Fragment analysis of the p53 gene in ovarian tumors.
Lianidou ES, Angelopoulou K, Katsaros D, Durando A, Massobrio M, Diamandis EP.
Clin Biochem 1998 Oct;31:551-3. Erratum in: Clin Biochem 1999 Mar;32:155. Massdario M [corrected to Massobrio M].
Abstract link: www.ncbi.nlm.nih.gov/pubmed/9812175

14. A highly sensitive enzyme-amplified lanthanide luminescence immunoassay for interleukin 6.
Bathrellos LM, Lianidou ES, Ioannou PC.
Clin Chem 1998 Jun;44:1351-3
Abstract link: www.ncbi.nlm.nih.gov/pubmed/9625068

13. Application of terbium sensitized fluorescence for the determination of fluoroquinolone antibiotics pefloxacin, ciprofloxacin and norfloxacin in serum.
Veiopoulou CJ, Ioannou PC, Lianidou ES.
J Pharm Biomed Anal 1997 Aug;15:1839-44
Abstract link: www.ncbi.nlm.nih.gov/pubmed/9278888

12. BRCA1 tumor suppressor gene product shares immunoreactive epitopes with a protein present in seminal plasma.
Lianidou ES, Melegos DN, Diamandis EP.
Clin Biochem 1997 Jul;30:425-32
Abstract link: www.ncbi.nlm.nih.gov/pubmed/9253520

11. Simple spectrofluorometric determination of p-aminobenzoic and p-aminosalicylic acids in biological fluids by use of terbium-sensitized luminescence.
Lianidou ES, Ioannou PC.
Clin Chem 1996 Oct;42:1659-65
Abstract link: www.ncbi.nlm.nih.gov/pubmed/8855151

10. Synchronous scanning second derivative spectrofluorimetry for the simultaneous determination of diflunisal and salicylic acid added to serum and urine as ternary complexes with terbium and EDTA.
E.S.Lianidou, P.C.Ioannou, C.K.Polydorou, C.E.Efstathiou.
Anal Chim Acta 1996;320:107-114
Abstract link: www.sciencedirect.com/science/article/pii/000326709500517X 

9. Comparative study of fluorescent ternary terbium complexes. Application in enzyme amplified fluorimetric immunoassay for a-fetoprotein.
C.J. Veiopoulou, Lianidou ES, P.C. Ioannou and C.E. Efstathiou.
Anal Chim Acta 1996;335:177-184
Abstract link: www.sciencedirect.com/science/article/pii/S0003267096003753

8. A simple, rapid, and sensitive spectrofluorimetric method for the determination of diflunisal in serum and urine based on its ternary complex with terbium and EDTA.
P.C.Ioannou, E.S.Lianidou, D.G.Konstantianos.
Anal Chim Acta 1995;300:237-241
Abstract link: www.sciencedirect.com/science/article/pii/000326709400415I

7. Second derivative synchronous scanning fluorescence spectrometry as sensitive detection technique in immunoassays.
Ε.S. Lianidou, P.C.Ioannou, E.Sacharidou.
Anal Chim Acta 1994;290:159-165
Abstract link: www.sciencedirect.com/science/article/pii/0003267094800510

6. Assay of creatine kinase isoenzyme MB in serum with time-resolved immunofluorometry.
Lianidou ES, Christopoulos TK, Diamandis EP.
Clin Chem 1990 Sep;36:1679-83
Abstract link: www.ncbi.nlm.nih.gov/pubmed/2208711

5. Ultrasensitive time-resolved fluorescence method for alpha-fetoprotein.
Christopoulos TK, Lianidou ES, Diamandis EP.
Clin Chem 1990 Aug;36(8 Pt 1):1497-502
Abstract link: www.ncbi.nlm.nih.gov/pubmed/1696856

4. Determination of ursodeoxycholic acid in serum by a new fluorometric enzymatic method using 7 beta-hydroxysteroid dehydrogenase from Clostridium absonum.
Lianidou ES, Papastathopoulos DS, Siskos PA.
Anal Biochem 1989 Jun;179:341-6
Abstract link: www.ncbi.nlm.nih.gov/pubmed/2672876

3. Enzymatic fluorimetric determination of ursodeoxycholic acid in urine using Clostridium absonum 7β hydroxysteroid dehydrogenase.
E.S.Lianidou, D.S.Papastathopoulos, P.A.Siskos.
Anal Letters 1989; 22/10, 2265 2280

2. Enzymic fluorimetric determination of sulphated and non-sulphated primary bile acids in urine using a rapid solvolysis technique.
Lianidou ES, Papanastasiou-Diamandi A, Siskos PA
Analyst 1988 Sep;113:1459-63
Abstract link: www.ncbi.nlm.nih.gov/pubmed/3239825

1. Determination of kinetic parameters for 3 alpha-hydroxysteroid dehydrogenase using the five major bile acids and their conjugates as substrates and correlation with their structure and solubility.
Lianidou ES, Siskos PA
Analyst 1987 Jun;112:753-5. Erratum in: Analyst 1987 Nov;112:1634.
Abstract link: www.ncbi.nlm.nih.gov/pubmed/3475990